Omar E. Franco

mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment.

This study shows that mTOR inhibition with everolimus enhances antitumor immune responses in TP53-mutant HNSCC by altering the tumor microenvironment.

A MYC Family Switch: L-MYC Drives and Maintains Neuroendocrine Lineage Programs in Prostate Cancer

This study identifies MYCL as a key driver of neuroendocrine lineage programs in prostate cancer by showing its upregulation in NEPC and its role in suppressing AR signaling and inducing neuroendocrine reprogramming.

DGAT1 as a Racially Divergent Driver of Carcinoma-Associated Fibroblast Activation Drives Tumorigenic Pathways via ERK1/2 Signaling in Prostate Cancer.

Immune cell single-cell RNA sequencing analyses link an age-associated T cell subset to symptomatic benign prostatic hyperplasia

The paper links an age-associated CD8+ T cell subset to symptomatic benign prostatic hyperplasia through immune aging mechanisms.

Infiltrating lipid-rich macrophage subpopulations identified as a regulator of increasing prostate size in human benign prostatic hyperplasia

The paper identifies lipid-rich macrophage subpopulations in BPH that correlate with prostate size and urinary symptoms.

High-throughput propagation of human prostate tissue from induced-pluripotent stem cells

This paper introduces a high-throughput method to generate human prostate tissue from induced pluripotent stem cells using co-culture with urogenital sinus mesenchyme.

Stromal Reactivity Differentially Drives Tumor Cell Evolution and Prostate Cancer Progression

This study develops a hybrid model showing stromal reactivity influences prostate cancer progression and prognosis by shaping tumor cell evolution and aggressiveness.